Speaking at WSJ Opinion Live in Washington, D.C., WSJ Editorial Page Editor Paul Gigot and SandboxAQ CEO Jack Hidary discuss Large Quantitative Models (LQMs) and their role in AI applications, the ...

Jon McNeill, DVx Ventures co-founder and CEO, former Tesla president and 'The Algorithm' author joins 'Squawk Box' to discuss a workflow followed by Tesla workers to help drive innovation. Got a ...

Maze Therapeutics (MAZE) plunged ~37% on Wednesday despite reporting encouraging initial data from a Phase 2 trial for its lead asset, MZE829, targeted at broad APOL1-mediated kidney disease, a ...

Maze Therapeutics has revealed topline phase 2 data for its lead kidney disease candidate that has analysts heralding its “best-in-class potential.” The once-daily oral small molecule APOL1 inhibitor, ...

A Canadian who has worked in the gaming industry for over two decades, Beck grew up on games such as Final Fantasy and Super Mario Bros. He specalizes in roleplaying games, but covers titles in almost ...

In the months following Elon Musk’s $44 billion acquisition of Twitter in 2022, my experience with the platform (and perhaps yours too) got quickly, dramatically worse. My algorithmic timeline, better ...

In case you had any doubt, Elon Musk’s X has an algorithm that favors conservative content posted by political activists over liberal content or posts by traditional news media accounts, according to ...

Chief Medical Officer Harold Bernstein exercised 15,000 shares, which were sold immediately for a total transaction value of approximately $690,300 on Feb. 2, 2026. Maze Therapeutics recently hit its ...

Maze Therapeutics (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, visits the Nasdaq MarketSite ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. TikTok has reached a deal that will allow it to keep operating in the ...